Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].

Orvosi hetilap - 6 Nov 2011

Iványi János László, Marton Eva, Plander Márk

Abstract excerpt

UNLABELLED: In Philadelphia chromosome-negative chronic myeloproliferative neoplasia, i.e. polycythemia vera, essential thrombocythemia and primary idiopathic myelofibrosis enhanced risk of thrombosis could be connected with Janus kinase 2 gene mutation occurring in various frequency in these diseases (JAK2V617F). Since 2002 the presence of JAK2 mutation in chronic myeloproliferative neoplasia has been regularly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow Neoplasms
Share to Myeloproliferative Disorders
Share to Phenylalanine

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Polycythemia Vera

Share to Primary Myelofibrosis

Share to Thrombocythemia, Essential

Share to Thrombosis

Share to Valine

Source

Identifiers

PMID: 22011365
DOI: 10.1556/OH.2011.29226

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].PMID 22011365Read ↗

[The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].Semantic proximity Read ↗

[Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].Semantic proximity Read ↗

Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders.Semantic proximity Read ↗

[Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].Semantic proximity Read ↗

[Myeloproliferative diseases caused by JAK2 mutation].Semantic proximity Read ↗

JAK2 mutation-related disease and thrombosis.Semantic proximity Read ↗

[Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection].Semantic proximity Read ↗

[Correlative study between JAK2 mutation and thrombosis in patients with myeloproliferative neoplasm].Semantic proximity Read ↗

JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.Semantic proximity Read ↗

JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.Semantic proximity Read ↗

[Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].Semantic proximity Read ↗

[New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.